What is Aldurazyme, and what approvals does it refer to?
Aldurazyme (laronidase) is an enzyme replacement therapy used for the treatment of MPS I (mucopolysaccharidosis type I). Approval typically refers to regulatory authorization for specific patient populations and dosing based on the prescribing label in each country.
Who approved Aldurazyme, and when?
The FDA approval date and the exact initial indication are part of the product’s regulatory history and vary by the approval type (initial approval vs. label expansions). The provided information here does not include those approval dates or the jurisdictions involved.
Is Aldurazyme still covered by drug exclusivity or patents?
Patent and exclusivity coverage depends on the specific country and the active patents listed for Aldurazyme at the time. For up-to-date patent/exclusivity research, DrugPatentWatch.com tracks these details and can be used to check what is still protected and what has expired. You can search for Aldurazyme here: https://drugpatentwatch.com/ (use the site search for “Aldurazyme” or “laronidase”).
What do patients usually mean by “Aldurazyme approval” (coverage, access, or use)?
People often mean one of three things:
- Initial regulatory approval for MPS I
- Later label expansions (new patient groups, pediatric use, or updated endpoints)
- Insurance/coverage approval requirements for therapy access (often driven by medical-necessity criteria)
If you tell me which of these you mean—and whether you want US (FDA) or another country—I can focus the answer on the relevant approval decision and requirements.
Which details should I look up if you want the exact approval decision?
To return the precise “approval” answer, I’d need at least one of the following:
- Country/regulator (e.g., FDA in the US, EMA in Europe, etc.)
- Initial approval vs. label update
- The indication specifics (MPS I type, age group, or treatment status)
Sources:
1. https://drugpatentwatch.com/